Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?

Research output: Contribution to journalArticle

Abstract

Recent news of an impending clinical cell transplantation trial in Parkinson's disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on discussions held by a global collaborative initiative on translation of stem cell therapy in Parkinson's disease, we have identified a set of key questions that we believe should be addressed ahead of every clinical stem cell-based transplantation trial in this disorder. In this article, we first provide a short history of cell therapy in Parkinson's disease and briefly describe the current state-of-art regarding human stem cell-derived dopamine neurons for use in any patient trial. With this background information as a foundation, we then discuss each of the key questions in relation to the upcoming therapeutic trial and critically assess if the time is ripe for clinical translation of parthenogenetic stem cell technology in Parkinson's disease.

Details

Authors
Organisations
External organisations
  • University of Cambridge
  • University of Melbourne
  • Van Andel Research Institute
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cell and Molecular Biology
Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalJournal of Parkinson's Disease
Volume6
Issue number1
Publication statusPublished - 2016
Publication categoryResearch
Peer-reviewedYes